SequelSEC

Prelude Therapeutics Inc PRLD

Pharmaceutical Preparations · CIK 0001678660 · Fiscal year ends 1231

Revenue
$12.14M
Fiscal year ended 2025-12-31
Operating income
-$104.57M
Fiscal year ended 2025-12-31
Free cash flow
-$56.37M
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$14.40MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.23Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue1.2×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity0.2×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth73.4%81th
Current ratio1.99x28th
R&D / revenue776.8%72th
CapEx / revenue0.6%31th
SBC / revenue98.1%68th
FCF margin-464.3%33th
Net margin-819.6%34th
Operating margin-861.3%36th

Prelude Therapeutics Inc (PRLD) reported revenue of $12.14M and net income of -$99.50M for the fiscal year ended 2025-12-31. This page shows 2 annual periods of income statement, balance sheet and cash flow figures normalized from Prelude Therapeutics Inc’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Prelude Therapeutics Inc income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Revenue$12.14M$7.00M
Cost of revenueUnavailableUnavailable
Gross profitUnavailableUnavailable
Operating income-$104.57M-$139.71M
Net income-$99.50M-$127.17M
Research & development$94.30M$118.00M
Weighted-average diluted sharesshares 76.96Mshares 75.81M
Pretax incomeUnavailableUnavailable
Income tax expense$0$0
Diluted EPS$-1.29$-1.68
Selling, general & administrativeUnavailableUnavailable
General & administrative$22.41M$28.72M
Selling & marketingUnavailableUnavailable

Balance

Prelude Therapeutics Inc balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Cash & equivalents$35.26M$12.47M
Total assets$141.32M$175.52M
Current assets$105.69M$135.90M
Total liabilities$72.68M$44.06M
Current liabilities$52.99M$25.64M
Total equity incl. NCI$68.64M$131.46M
Temporary (mezzanine) equityUnavailableUnavailable
InventoryUnavailableUnavailable
Accounts receivableUnavailableUnavailable
GoodwillUnavailableUnavailable
Long-term debtUnavailableUnavailable
Accounts payable$3.98M$7.73M

Cash flow

Prelude Therapeutics Inc cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Operating cash flow-$56.30M-$102.89M
Capital expenditures$67.00K$764.00K
Investing cash flow$53.46M$90.19M
Financing cash flow$24.82M-$120.00K
Net change in cash$21.97M-$12.82M
Stock-based compensation$11.91M$21.34M
Common dividends paidUnavailableUnavailable
Common share repurchasesUnavailableUnavailable
Depreciation & amortization$1.71M$1.77M

Derived

Prelude Therapeutics Inc derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Free cash flow-$56.37M-$103.65M
Gross marginUnavailableUnavailable
Operating margin-861.3%-1995.9%
FCF margin-464.3%-1480.7%
SBC / revenue98.1%304.9%
Current ratio1.99x5.30x
Revenue YoY growth73.4%Unavailable
Net margin-819.6%-1816.8%
R&D / revenue776.8%1685.6%
CapEx / revenue0.6%10.9%
Long-term debt / equityUnavailableUnavailable
Effective tax rateUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PRLD in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-10View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-06View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.